{"id":33487,"date":"2025-05-20T14:00:00","date_gmt":"2025-05-20T12:00:00","guid":{"rendered":"https:\/\/dupmecp2.eu\/?p=33487"},"modified":"2025-09-10T08:37:22","modified_gmt":"2025-09-10T06:37:22","slug":"early-results-hero","status":"publish","type":"post","link":"https:\/\/dupmecp2.eu\/de\/early-results-hero\/","title":{"rendered":"Vielversprechende erste Ergebnisse der HERO-Studie f\u00fcr das MECP2-Duplikationssyndrom"},"content":{"rendered":"

Anfang dieses Jahres nahm Alvin Luk an der CRISPR Medicine Conference<\/em> in Copenhagen teil, um ein Update zur HERO-Studie f\u00fcr das MECP2-Duplikationssyndrom zu geben. Alvins Pr\u00e4sentation ist f\u00fcr die Gemeinschaft auf YouTube verf\u00fcgbar.<\/p>\n\n\n\n

In diesem Video erfahren Sie mehr \u00fcber Huidagenes experimentelle CRISPR-Cas13-Therapie HG204<\/strong>und sehen die Fortschritte beim ersten behandelten Kind, drei Monate nach Erhalt des Pr\u00fcfmedikaments. Springen Sie zu Minute 26:00<\/strong> f\u00fcr Videoaufnahmen des Patienten.<\/p>\n\n\n\n

Diese fr\u00fchen Ergebnisse sind sehr ermutigend und deuten weiter darauf hin, dass die Wiederherstellung der MeCP2-Proteinspiegel eine vielversprechende Strategie zur Bek\u00e4mpfung von MDS sein k\u00f6nnte.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n
\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n\n\n\n
\"\"<\/figure>\n<\/figure>\n\n\n\n

Ein zweites Kind wurde bereits mit HG204 behandelt, und es wird erwartet, dass bis zu sechs Patienten nacheinander in diese Studie in China aufgenommen werden.<\/p>\n\n\n\n

\n
Video ansehen<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du […]<\/p>","protected":false},"author":1,"featured_media":33493,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7,201],"tags":[],"class_list":["post-33487","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualite","category-recherche-fr"],"yoast_head":"\nR\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2<\/title>\n<meta name=\"description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/dupmecp2.eu\/de\/early-results-hero\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\" \/>\n<meta property=\"og:description\" content=\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/dupmecp2.eu\/de\/early-results-hero\/\" \/>\n<meta property=\"og:site_name\" content=\"DupMECP2\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-20T12:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-10T06:37:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Caroline\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"Caroline\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"author\":{\"name\":\"Caroline\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\"},\"headline\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"},\"wordCount\":167,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"articleSection\":[\"Actualit\u00e9\",\"Recherche\"],\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"url\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\",\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2\",\"isPartOf\":{\"@id\":\"https:\/\/dupmecp2.eu\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"datePublished\":\"2025-05-20T12:00:00+00:00\",\"dateModified\":\"2025-09-10T06:37:22+00:00\",\"description\":\"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.\",\"breadcrumb\":{\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage\",\"url\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"contentUrl\":\"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg\",\"width\":1080,\"height\":1080},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/dupmecp2.eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Recherche\",\"item\":\"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/dupmecp2.eu\/#website\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"name\":\"DupMECP2\",\"description\":\"EU\",\"publisher\":{\"@id\":\"https:\/\/dupmecp2.eu\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/dupmecp2.eu\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/dupmecp2.eu\/#organization\",\"name\":\"DupMECP2\",\"url\":\"https:\/\/dupmecp2.eu\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"DupMECP2\"},\"image\":{\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee\",\"name\":\"Caroline\",\"sameAs\":[\"https:\/\/dupmecp2.eu\"],\"url\":\"https:\/\/dupmecp2.eu\/de\/author\/417a2385dc37aa45\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vielversprechende erste Ergebnisse der HERO-Studie f\u00fcr das MECP2-Duplikationssyndrom - DupMECP2","description":"Anfang dieses Jahres nahm Alvin Luk an der CRISPR Medicine Conference in Copenhagen teil, um ein Update zur HERO-Studie f\u00fcr das MECP2-Duplikationssyndrom zu geben. Alvins Pr\u00e4sentation ist f\u00fcr die Gemeinschaft auf YouTube verf\u00fcgbar.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/dupmecp2.eu\/de\/early-results-hero\/","og_locale":"de_DE","og_type":"article","og_title":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome - DupMECP2","og_description":"Plus t\u00f4t cette ann\u00e9e, Alvin Luk a particip\u00e9 \u00e0 la conf\u00e9rence CRISPR Medicine \u00e0 Copenhagen afin de pr\u00e9senter les nouveaut\u00e9s sur l\u2019essai clinique HERO pour le syndrome de duplication du g\u00e8ne MECP2. Sa pr\u00e9sentation est disponible sur YouTube pour la communaut\u00e9.","og_url":"https:\/\/dupmecp2.eu\/de\/early-results-hero\/","og_site_name":"DupMECP2","article_published_time":"2025-05-20T12:00:00+00:00","article_modified_time":"2025-09-10T06:37:22+00:00","og_image":[{"width":1080,"height":1080,"url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","type":"image\/jpeg"}],"author":"Caroline","twitter_card":"summary_large_image","twitter_misc":{"Verfasst von":"Caroline","Gesch\u00e4tzte Lesezeit":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#article","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"author":{"name":"Caroline","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee"},"headline":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","mainEntityOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"},"wordCount":167,"commentCount":0,"publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","articleSection":["Actualit\u00e9","Recherche"],"inLanguage":"de","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","url":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/","name":"Vielversprechende erste Ergebnisse der HERO-Studie f\u00fcr das MECP2-Duplikationssyndrom - DupMECP2","isPartOf":{"@id":"https:\/\/dupmecp2.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"image":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage"},"thumbnailUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","datePublished":"2025-05-20T12:00:00+00:00","dateModified":"2025-09-10T06:37:22+00:00","description":"Anfang dieses Jahres nahm Alvin Luk an der CRISPR Medicine Conference in Copenhagen teil, um ein Update zur HERO-Studie f\u00fcr das MECP2-Duplikationssyndrom zu geben. Alvins Pr\u00e4sentation ist f\u00fcr die Gemeinschaft auf YouTube verf\u00fcgbar.","breadcrumb":{"@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#primaryimage","url":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","contentUrl":"https:\/\/dupmecp2.eu\/wp-content\/uploads\/2025\/09\/HERO-update.jpg","width":1080,"height":1080},{"@type":"BreadcrumbList","@id":"https:\/\/dupmecp2.eu\/resultats-preliminaires-hero\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/dupmecp2.eu\/"},{"@type":"ListItem","position":2,"name":"Recherche","item":"https:\/\/dupmecp2.eu\/category\/recherche-fr\/?lang=fr"},{"@type":"ListItem","position":3,"name":"R\u00e9sultats pr\u00e9liminaires prometteurs de l\u2019essai HERO pour le syndrome"}]},{"@type":"WebSite","@id":"https:\/\/dupmecp2.eu\/#website","url":"https:\/\/dupmecp2.eu\/","name":"DupMECP2","description":"EU","publisher":{"@id":"https:\/\/dupmecp2.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/dupmecp2.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Organization","@id":"https:\/\/dupmecp2.eu\/#organization","name":"DupMECP2","url":"https:\/\/dupmecp2.eu\/","logo":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"DupMECP2"},"image":{"@id":"https:\/\/dupmecp2.eu\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/dupmecp2.eu\/#\/schema\/person\/b41e8cbba153cd974ee340386af279ee","name":"Caroline","sameAs":["https:\/\/dupmecp2.eu"],"url":"https:\/\/dupmecp2.eu\/de\/author\/417a2385dc37aa45\/"}]}},"_links":{"self":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/33487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/comments?post=33487"}],"version-history":[{"count":2,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/33487\/revisions"}],"predecessor-version":[{"id":33494,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/posts\/33487\/revisions\/33494"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/media\/33493"}],"wp:attachment":[{"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/media?parent=33487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/categories?post=33487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dupmecp2.eu\/de\/wp-json\/wp\/v2\/tags?post=33487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}